AVP and atherosclerosis: Increased levels of copeptin lead to impaired glucose metabolism by intensifying the process of gluconeogenesis and glycogenolysis, as well as lipids—increasing the level of triglycerides and reducing the level of HDL cholesterol, these changes are closely correlated with the development of metabolic syndrome, abdominal obesity, and atherosclerosis [83].